Front Range Biosciences Applauds Signing of Colorado Hemp Bills; Advocates on Behalf of Hemp Industry at FDA Hearing on CBD
June 4th, 2019
DENVER and WASHINGTON, June 4, 2019 /PRNewswire/ — Front Range Biosciences® (“FRB”), which provides hemp, coffee, and high-value crop producers with high-performing Clean Stock® plants and seed by combining the best practices in agriculture with innovative technologies, applauds the State of Colorado on the signing of bills SB-220 “Hemp Regulation Alignment with 2018 Federal Farm Bill” and SB-240 “Industrial Hemp Products Regulation.”
Dr. Jonathan Vaught, CEO of FRB, said, “The signing of SB-220 and SB-240 into law by Governor Polis is a major step for the hemp industry in Colorado, bringing state policy in line with the 2018 Federal Farm Bill. This allows Colorado’s hemp program to continue on its high growth trajectory, providing more opportunities for farmers in the state to thrive and contribute to the exploding global market for cannabinoid products. FRB is proud to stand alongside so many other Colorado hemp companies as leaders in the fight to legalize and appropriately regulate hemp. Governor Polis has been a strong advocate for the hemp industry and we were honored to host his signing of SB-220 and SB-240 in our Denver greenhouse facility.”
Additionally, Dr. Vaught presented at the FDA’s Scientific Data & Information about Products Containing Cannabis or Cannabis-Derived Compounds public hearing on Friday, May 31. Industry leaders in agriculture, manufacturing, health, retail, and academia were given the opportunity to speak directly to the agency on these key operational components. Dr. Vaught’s testimony focused on the current data backing the safety of cannabinoid products, positive agricultural impacts, and the segments of the U.S. economy that would thrive with the commercialization of cannabis and cannabis-derived compounds.
“The hearing illustrated that it is imperative for the industry to collaborate with the FDA and similar regulatory bodies to develop a system of stringent requirements and standardized practices to ensure the safety and efficacy of these products,” said Dr. Vaught. “Concurrently, it is important that regulations do not create a monopoly for any one segment of the industry, and that sectors like dietary supplements, pharmaceuticals, food additives, and cosmetics work together to supply the FDA with its respective data and information to exemplify the myriad of benefits this plant has to offer.”
The cannabis industry has the opportunity to engage directly with the FDA now until July 2, providing suggestions for the creation of an optimal structure in order to utilize cannabis to its full potential. FRB encourages different industry segments to submit scientific data and regulatory proposals that supports the safety of cannabinoid ingredients and its continued growth trajectory. Research and data points can be submitted here.
Watch Dr. Vaught’s testimony to the FDA in full here.
For more information on Front Range Biosciences, please visit http://www.frontrangebio.com
About Front Range Biosciences
FRB is an agricultural biotech company that specializes in tissue culture propagation of high-value crops at industrial scale to improve consistency and efficiency for clone production. FRB also has an advanced breeding program for identifying and improving commercially relevant traits. FRB is located in Lafayette, Colorado.
North 6th Agency
SOURCE Front Range Biosciences
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.